NexgenRx Inc (NEGXF) Stock Price, Trades & News

NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	13.62
Equity-to-Asset	0.22
Debt-to-Equity	0.04
Debt-to-EBITDA	0.09
Interest Coverage	112.77
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.37	Distress Grey Safe
Beneish M-Score	-2.97	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

3/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	8.6
	3-Year EBITDA Growth Rate	23.1
	3-Year FCF Growth Rate	95.7
	3-Year Book Growth Rate	-6.3

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	100
	9-Day RSI	99.97
	14-Day RSI	99.67
	6-1 Month Momentum %	-3.57
	12-1 Month Momentum %	35

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.16
	Quick Ratio	1.16
	Cash Ratio	0.15
	Days Sales Outstanding	17.74
	Days Payable	100.48

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.25
	Dividend Payout Ratio	0.67
	3-Year Dividend Growth Rate	14.5
	Forward Dividend Yield %	2.26
	5-Year Yield-on-Cost %	2.25
	3-Year Average Share Buyback Ratio	-0.4
	Shareholder Yield %	2.56

Profitability Rank

6/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	84.68
	Operating Margin %	15.95
	Net Margin %	10.83
	EBITDA Margin %	20.68
	FCF Margin %	23.78
	OCF Margin %	25.47
	ROE %	24.32
	ROA %	5.38
	ROIC %	6.67
	ROC (Joel Greenblatt) %	186.61
	ROCE %	31.13
	Years of Profitability over Past 10-Year	5
	Moat Score	3
	Tariff Resilience Score	7

GF Value Rank

	Name	Current	Vs Industry		Vs History
	PE Ratio	18.75
	PE Ratio without NRI	17.31
	Shiller PE Ratio	36.74
	Price-to-Owner-Earnings	8.65
	PS Ratio	1.89
	PB Ratio	4.46
	Price-to-Tangible-Book	6.5
	Price-to-Free-Cash-Flow	7.89
	Price-to-Operating-Cash-Flow	7.38
	EV-to-EBIT	11.01
	EV-to-EBITDA	7.7
	EV-to-Revenue	1.59
	EV-to-FCF	6.69
	Price-to-GF-Value	1.2
	Price-to-Projected-FCF	1.3
	Price-to-Median-PS-Value	1.05
	Price-to-Graham-Number	2.32
	Price-to-Net-Current-Asset-Value	10.83
	Earnings Yield (Greenblatt) %	9.08
	FCF Yield %	13.68
	Forward Rate of Return (Yacktman) %	2.89

Financials

Annual Quarterly TTM

NEGXF's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with OTCPK:NEGXF

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

NexgenRx Inc Executives

Details

GF Value™: $0.27

NEGXF

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with NEGXF. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	13.363
	EPS (TTM) ($)	0.018
	Beta	0.1362
	3-Year Sharpe Ratio	0.08
	3-Year Sortino Ratio	0.19
	Volatility %	45.09
	14-Day RSI	99.67
	14-Day ATR ($)	0.001204
	20-Day SMA ($)	0.31675
	12-1 Month Momentum %	35
	52-Week Range ($)	0.2 - 0.325
	Shares Outstanding (Mil)	71.12

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

NexgenRx Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

NexgenRx Inc Stock Events

Financials Calendars

Event	Date	Price ($)
CAD 0.005000 Cash Dividend	2026-04-24	0.27 (+0.00%)
CAD 0.005000 Cash Dividend	2025-12-17	0.28 (+0.00%)
CAD 0.005000 Cash Dividend	2025-08-25	0.20 (+0.00%)
CAD 0.005000 Cash Dividend	2025-04-25	0.20 (+0.00%)
CAD 0.005000 Cash Dividend	2024-12-16	0.20 (+0.00%)

Show

Entries

NexgenRx Inc Frequently Asked Questions

What is NexgenRx Inc(NEGXF)'s stock price today?

The current price of NEGXF is $0.33. The 52 week high of NEGXF is $0.33 and 52 week low is $0.20.

When is next earnings date of NexgenRx Inc(NEGXF)?

The next earnings date of NexgenRx Inc(NEGXF) is .

Does NexgenRx Inc(NEGXF) pay dividends? If so, how much?

The Dividend Yield % of NexgenRx Inc(NEGXF) is 2.25% (As of Today), Highest Dividend Payout Ratio of NexgenRx Inc(NEGXF) was 2. The lowest was 0.67. And the median was 1.5. The Forward Dividend Yield % of NexgenRx Inc(NEGXF) is 2.26%. For more information regarding to dividend, please check our Dividend Page.

Guru Commentaries on OTCPK:NEGXF

No articles.

Press Release

	Subject	Date
	Nexgenrx Announces Declaration of Divdend	2026-04-17
	NexgenRx Announces 2025 Year End Results with Continued Increasing Net Income, EBITDA And Revenue Growth	2026-03-31
	NexgenRx Announces Declaration of Divdends	2025-12-10
	NexgenRx Announces Significant Third Quarter Revenue and EBITDA Growth	2025-11-20
	NexgenRx Announces Declaration of Dividend	2025-08-15
	NexgenRx Announces Second Quarter Results with Significant Revenue Growth and Positive EBITDA	2025-08-12
	NexgenRx Announces First Quarter Results With Solid Revenue Growth and Positive EBITDA	2025-05-15
	NexgenRx Announces Declaration of Divdend	2025-04-17
	NexgenRx Announces 2024 Year End Results with Continued Strong Revenue Growth and Increasing Positive EBITDA	2025-04-03
	NexgenRx Announces Third Quarter Results and Declaration of Divdend	2024-11-25

10/Page

Articles on NexgenRx Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.